rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PRLD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Prelude Therapeutics Incorporated (PRLD) Reports Q3 Loss, Beats Revenue Estimates
      Nov 16Yahoo FinancePRLD
      Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
      Nov 4Yahoo FinancePRLD
      Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
      Oct 23Yahoo FinanceINCYPRLD
      Prelude Therapeutics at Chardan conference: bet on selective degraders
      Oct 20Investing.comPRLD
      Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround

      Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

      Oct 16Yahoo FinancePRLD
      Prelude Therapeutics to Participate in the Chardan Healthcare Conference
      Oct 16Yahoo FinancePRLD
      H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy
      Oct 14Investing.comPRLD
      Citizens reiterates Prelude Therapeutics stock rating on Lilly deal
      Oct 14Investing.comPRLD
      Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
      Oct 13Yahoo FinancePRLD
      Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
      Oct 13Yahoo FinancePRLD
      Prelude partners with Lilly for breast cancer drug trial
      Oct 13Investing.comPRLD
      Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers
      Oct 5Yahoo FinancePRLD
      JPMorgan initiates Prelude Therapeutics stock at Overweight on drug potential
      Sep 17Investing.comPRLD
      Prelude Therapeutics at H.C. Wainwright conference: pipeline gains momentum
      Sep 16Investing.comPRLD
      Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

      WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City September 14-16, 2026. On Wednesday, September 16, 2026, at 10:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Charles Morris, MBChB, MRCP. Chief Medical Officer, Peggy Scherle,

      Sep 11Yahoo FinancePRLD
      Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial

      Prelude Therapeutics (PRLD) said Thursday that the US Food and Drug Administration cleared its appli

      Sep 10Yahoo FinancePRLD
      Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
      Sep 10Yahoo FinancePRLD
      Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD)

      Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.

      Aug 23Seeking AlphaPRLD

      This is the newest page. Registered accounts read further back.